Intelligence Profile
Clinical Applications
Pancragen is a tetrapeptide (Lys-Glu-Asp-Trp-NH2) that has been investigated primarily for metabolic and pancreatic function disorders, particularly in the context of aging. The available evidence comes exclusively from preclinical studies, with no human clinical trials identified in the literature.
Primary Applications Under Investigation
Glucose Metabolism Disorders
Pancragen has been studied for correcting impaired glucose tolerance, specifically in aging populations. Research in old female rhesus monkeys (2015) demonstrated its potential to address glucose metabolism dysfunction associated with aging. Additional studies in experimental diabetes models showed effects on blood glucose levels in rats.
Pancreatic Function Support
Multiple studies have examined Pancragen's impact on pancreatic endocrine function. Research from 2014 investigated its effects on pancreatic endocrine function in old monkeys, while earlier work (2012) showed the tetrapeptide could stimulate functional activity of pancreatic cells during aging.
Age-Related Metabolic Disorders
A 2011 study explored the prospects of using Pancragen for correcting metabolic disorders in elderly populations, suggesting potential applications in age-related metabolic dysfunction.
Mechanism of Action
Research indicates that Pancragen may work by stimulating pancreatic cell differentiation during aging (2013) and appears to have tissue-specific effects on cell differentiation in aging tissues more broadly (2012). The compound has also shown effects on capillary permeability and adhesion in experimental models.
Limitations of Current Evidence
Important Clinical Considerations:
- All available evidence comes from animal studies (primarily rats and monkeys)
- No human clinical trials have been identified
- The evidence base is relatively limited, consisting mainly of studies from Russian research groups
- Long-term safety and efficacy data in humans are not available
This is not medical advice. Consult healthcare providers before considering any therapeutic applications, as human safety and efficacy data are lacking.